Key result
This review summarizes the common presentations, major risk factors, diagnostic pitfalls, therapeutic approaches, and prevention strategies for TAVR-related infective endocarditis.
Why the study?
TAVR-related infective endocarditis is expected to increase as indications expand to younger patients, and carries an overall poor prognosis requiring clinicians to understand its presentation, risk factors, diagnosis, and management.
This review provides an updated overview of the clinical presentation, risk factors, diagnosis, management, and prevention of TAVR-related infective endocarditis.
TAVR-IE vigilance is warranted with expanding younger-patient indications; leaves open optimal prevention and management strategies for prospective trials.
Transcatheter aortic valve replacement (TAVR) use is gaining momentum as the mainstay for the treatment of aortic stenosis compared to surgical aortic valve replacement (SAVR). Unfortunately, TAVR-related infective endocarditis (TAVR-IE) is expected to be detected more and more as a result of the ever-expanding indications in younger patients. Given the overall poor prognosis of TAVR-IE, it is imperative that clinicians familiarize themselves with common presentations, major risk factors, diagnostic pitfalls, therapeutic approaches, and the prevention of TAVR-IE. Herein, we review all of the above in detail with the most updated available literature.
No takes yet. Share an insight, caveat, or question.
Braghieri et al. (2023) conducted a review in TAVR-related infective endocarditis. Transcatheter aortic valve replacement was evaluated. This review summarizes the common presentations, major risk factors, diagnostic pitfalls, therapeutic approaches, and prevention strategies for TAVR-related infective endocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: